Technology Appraisal Committee Meeting Committee C

Minutes: Confirmed

Date and Time: Wednesday 9 November 2016, 10:00 – 14:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Chair Professor Andrew Stevens Present for all notes
2. Professor Andrea Manca Present for all notes
3. Dr Anna O’Neill Present for all notes
4. David Chandler Present for notes 01 to 06
5. Professor Eugene Milne Present for all notes
6. Gail Coster Present for all notes
7. Dr Iain Miller Present for all notes
8. Dr Judith Wardle Present for all notes
9. Mr Kamal Balakrishnan Present for all notes
10. Professor Kathryn Abel Present for all notes
11. Professor Matt Stevenson Present for all notes
12. Mr Michael Chambers Present for all notes
13. Dr Prithviraj Das Present for all notes
14. Dr Paul Tappenden Present for all notes
15. Professor Rachel Elliott Present for all notes
16. Professor Stephen O’Brien Present for notes 01 to 06

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Dr Frances Sutcliffe Associate Director, National Institute for Health and Care Excellence Present for all notes

Stephanie Yates Project Manager, National Institute for Health and Care Excellence Present for all notes

Joanne Ekeledo Administrator, National Institute for Health and Care Excellence Present for all notes

Thomas Paling Technical Analyst, National Institute for Present for notes 01 to 06
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma and Apremilast for treating active psoriatic arthritis (rapid review TA372).

2. Apologies were received from Professor Andrew Renehan, Professor Robert Walton, Dr Peter Selby and Dr Nigel Langford.

Any other Business

3. None

Appraisal of Brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma

Part 1 – Open session

4. The Chair welcomed company representatives from Takeda to the meeting.

5. The Chair asked all Committee members to declare any relevant interests
5.1. Professor Andrea Manca, Dr Anna O’Neill, David Chandler Professor Eugene Milne, Gail Coster, Dr Iain Miller, Dr Judith Wardle Mr Kamal Balakrishnan, Professor Kathryn Abel, Professor Matt Stevensen, Mr Michael Chambers Professor Stephen O’Brien, Dr Paul Tappenden, Professor Rachel Elliott and Dr Prithwiraj Das all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma.

5.2. Dr Prithwiraj Das declared a personal non-specific financial interest. He works for Boehringer Ingelheim Limited. Boehringer Ingelheim has some haematology-oncology molecules in the pipeline.

9.2.1 It was agreed that this declaration would not prevent Dr Prithwiraj Das from participating in this section of the meeting.

5.3. Mr Mike Chambers declared a personal non-specific financial interest. He is currently receiving funding from Takeda to undertake a multi-stakeholder project on real work evidence (IMI GetReal), but this does not involve working specifically on any of Takeda’s medicines.

9.3.1 It was agreed that this declaration would prevent Mr Mike Chambers from participating in this section of the meeting.

6. The Chair asked all NICE Staff to declare any relevant interests.

6.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma.

7. The Chair asked all other invited guests ERG and invited experts, not including observers) to declare their relevant interests.

7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma.

7.2. Andrea Berardi declared a personal non-specific financial interest. Since completing work on the original ERG report for this appraisal he now has a new position at Parexel where he will be involved in pembrolizumab in the same therapy area.

7.2.1. It was agreed that this declaration would not prevent Andrea Berardi from participating in this section of the meeting.

8. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
9. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

10. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

11. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

12. The Committee continued to discuss the clinical and cost effectiveness of brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma 12.1. The committee decision was based on consensus.

13. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of apremilast for treating active psoriatic arthritis (rapid review TA372)

Part 1 – Open session

14. The Chair welcomed company representatives from Celgene to the meeting.

15. The Chair asked all Committee members to declare any relevant interests

15.1. Professor Andrea Manca, Dr Anna O’Neill, Professor Eugene Milne, Gail Coster, Dr Iain Miller, Dr Judith Wardle, Mr Kamal Balakrishnan, Professor Kathryn Abel, Professor Matt Stevenson, Mr Michael Chambers, Dr Paul Tappenden, Professor Rachel Elliott and Dr Prithviraj Das all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of apremilast for treating active psoriatic arthritis (rapid review TA372).

15.2. Dr Iain Miller declared a personal non-specific financial interest. He will be undertaking consultancy work for Celgene. His work with the company will not relate to this drug, or to the indication under discussion.

9.2.1 It was agreed that this declaration would not prevent Dr Iain Miller from participating in this section of the meeting.

15.3. Dr Prithviraj Das declared a personal non-specific financial interest. He works for Boehringer Ingelheim Limited. Boehringer Ingelheim may have various early-phase molecules in the pipeline. He has not been involved in work in psoriatic arthritis in the last 12 months.

9.3.1 It was agreed that this declaration would prevent Dr Prithviraj Das from participating in this section of the meeting.
15.4. David Chandler is conflicted. He was the patient expert for the original appraisal and his employing organisation the Psoriasis and Psoriatic Arthritis Alliance is a listed as a stakeholder and submitted evidence in the previous appraisal.

16. The Chair asked all NICE Staff to declare any relevant interests.

16.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of apremilast for treating active psoriatic arthritis (rapid review TA372).

17. The Chair asked all other invited guests ERG and invited experts, not including observers) to declare their relevant interests.

17.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of apremilast for treating active psoriatic arthritis (rapid review TA372).

18. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

19. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

20. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

21. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

22. The Committee continued to discuss the clinical and cost effectiveness of apremilast for treating active psoriatic arthritis (rapid review TA372)

22.1. The committee decision was based on consensus.

23. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

24. Wednesday 18 January 2017, 10:00 to 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.